Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pepper patch could soothe teen nerve pain without pills

NCT ID NCT05997979

Symptom relief Sponsor: University Hospital, Brest Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a capsaicin 8% patch (made from chili pepper extract) can reduce chronic nerve pain in teenagers aged 12 to 17 who have had pain for over 3 months after surgery or injury. Half the teens get the real patch, the other half get a placebo dressing. Pain levels are checked before treatment and again 4 months later. The goal is to see if the patch offers better pain relief than a dummy treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
capsaicin 8% patch (QUTENZA®)
What this could lead to
If it works, this could offer a new, non-drug option to ease chronic nerve pain in teenagers after surgery or injury.
What could go wrong
This is a small early-phase trial with only 46 teens, so results may not apply to everyone. The patch can cause skin irritation or burning, and pain relief may not be long-lasting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 46 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2024

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 to 17 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Children aged 12 to 17 years (lower age limit of 12 has been chosen to ensure NPSI full filling). * Male or female. * Persistent neuropathic pain more than 3 months after surgery or trauma despite treatment following recommendations. * Neuropathic pain is defined as a DN4 score equal to or greater than 3/7 or 4/10, and localized in a nerve territory explained by the surgery or the trauma. * Treatment, survey and follow up must be realized in an identified investigating center of the study * For patients of childbearing potential: use of an adequate method of contraception\* during the course of the study through 48 hours after the last patch application (girls of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to the first patch application). * Adequate contraception includes sexual abstinence, progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action, male or female condom with or without spermicide, cap, diaphragm or sponge with spermicide, combination of male condom with either cap, diaphragm or sponge with spermicide (double barrier methods) Exclusion Criteria: * Intellectual deficiency not allowing full filling of NPSI. * Insufficient command of the French language to full fill NPSI and other evaluation tools. * Parents' refusal of consent. * Minor patients' opposition. * Underlying neurological disease. * Ongoing neurotoxic treatment. * Already treated by capsaicin. * Cutaneous lesion on pain area. * Patient presenting a pain area on the face, above the hairline of the scalp, and/or in proximity to mucous membranes * Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 of Qutenza SmPC.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Chronic Pain chronic pain syndrome neuralgia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic pain Neuropathic pain

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU d'Amiens

    RECRUITING

    Amiens, France

  • CHU d'Angers

    RECRUITING

    Angers, France

  • CHU de Bordeaux

    RECRUITING

    Bordeaux, France

  • CHU de Brest

    RECRUITING

    Brest, France

  • CHU de Lyon

    RECRUITING

    Lyon, France

  • CHU de Marseille

    RECRUITING

    Marseille, France

  • CHU de Montpellier

    RECRUITING

    Montpellier, France

  • CHU de Nantes

    RECRUITING

    Brest, France

  • CHU de Tours

    RECRUITING

    Tours, France

  • Institut Gustave Roussy

    RECRUITING

    Villejuif, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.